WVE
NASDAQ · Pharmaceuticals
Wave Life Sciences Ltd
$11.76
-0.36 (-2.97%)
Financial Highlights (FY 2026)
Revenue
147.08M
Net Income
-131,740,218
Gross Margin
—
Profit Margin
-89.6%
Rev Growth
+38.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 33.3% | 33.3% |
| Operating Margin | -101.9% | -91.7% | 30.2% | 30.2% |
| Profit Margin | -89.6% | -85.1% | 22.7% | 28.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 147.08M | 106.37M | 444.96M | 373.67M |
| Gross Profit | — | — | 148.35M | 124.58M |
| Operating Income | -149,936,722 | -97,586,816 | 134.59M | 112.68M |
| Net Income | -131,740,218 | -85,743,561 | 100.99M | 106.69M |
| Gross Margin | — | — | 33.3% | 33.3% |
| Operating Margin | -101.9% | -91.7% | 30.2% | 30.2% |
| Profit Margin | -89.6% | -85.1% | 22.7% | 28.6% |
| Rev Growth | +38.3% | +38.3% | +21.0% | +12.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 610.85M | 550.85M |
| Total Equity | — | — | 1.16B | 1.26B |
| D/E Ratio | — | — | 0.53 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -140,266,242 | -96,364,571 | 186.52M | 158.68M |
| Free Cash Flow | — | — | 121.04M | 98.75M |